Originally posted by Namron7
Happily, there’s a loophole:
Everyone – including the lawmakers – seems to have overlooked the fact that most of these herbs and supplements can be found in different types of shampoos you can buy off the shelf.
Apart from their timeworn and proven healing effects on HIV, cancer, leprosy, gunshot wounds and all kinds of infectious and genetic diseases/trauma, herbs and supplements have also always had a beneficial effect on hair:
• Camomile: smooth, glossy finish for brunette hair
• Oregano: gentle, natural gloss for all hair types
• Basil: mild, slightly astringent treatment for hair that tends to be greasy if left to its own ends
• Mint: a perfect natural antidote to dandruff, clinically proven
• Selenium (NB: not a herb): excellent for hair fibre strength and integrity
There are many more essential supplements and herbs to be found in lots of different shampoos. So if you can’t get your herbs/supplements from pills, you could definitely continue getting them from shampoos if push came to shove (at least for a time until they close the legal loophole).
Under the Traditional Herbal Medicinal Products Directive, a company needs to demonstrate the safety and efficacy of the herbal medicine through traditional use within the EU for at least 30 years or 15 years within the EU and 30 years outside the EU. Due to character of herbal medicine, it is very difficult or almost impossible for these herbal medicines to obtain licences. In the six years since the THMPD was initially passed in 2004, not one Chinese herbal medicine has managed to get a licence (correct at the time of writing). Thus, all Chinese herbal medicines will remain 'unlicensed', therefore no allow to import into Europe. It is effectively banning the import of ALL traditional herbal remedies such as Chinese herbal medicines. Moreover, Western and Ayurvedic (of Indian origin) herbal formulas will also be prohibited from all EU states.
1. Discrimination against non-European Herbal Traditions by requiring at least 15 out of 30 years of usage within the EU, as the basis for proving long established, traditional usage. The basis for this requirement is the supposedly varying pharmavigilance standards in different regions, implying that standards outside of Europe may be lower than those within Europe. This provision seriously disadvantages Ayurveda, Traditional Chinese Medicine, South East Asian, Tibetan, Amazonian and southern African traditions, which are among the longest and most developed botanically-based healthcare traditions worldwide.
2. Particular combinations of herbal products may be disallowed. ‘Traditional use’ under the THMPD is based on use of an individual herb or specific combination of herbs. It therefore prevents use of new or innovative combinations that might be supported by emerging science.
3. Products are subject to pharmaceutical criteria and GMPs. Under the THMPD, manufacturers must meet pharmaceutical GMPs, including purity and stability criteria that are identical to those used in the case of conventional pharmaceuticals, under the provisions of the same base Directive (2001/83/EC). These criteria cannot be met in the case of many poly-herbal products owing to the complexity of mixtures, the masking of known markers and, in other cases, the lack of standards for identification of markers.
4. Traditional medicines are eligible for registration only if they are intended for minor ailments, while traditional medical systems generally have developed to cater for the full range of ailments and diseases encountered in their indigenous environments. Accordingly, the registration scheme may be discriminatory against ethnic minorities within the EU who might wish to benefit from products associated with their traditional medical system. While food supplements are able to be sold legally within the EU containing ingredients that support the health (or reduce the disease risk) of, for example, cardiovascular or neurological systems, these are disallowed under the THMPD scheme.
5. Excessive cost of accessing the THMPD regime. The cost of meeting the data requirements for the THMPD, including the assembly of dossiers of bibliographic and expert evidence, as well as the requirements for genotoxicity data (which typically have to be commissioned as existing data are not available) is prohibitive for many SMEs.
6. Herbal Products containing significant levels of vitamins and minerals will be prohibited and allowed only if the action of those nutrients is considered ‘ancillary’ to that of the herbal ingredients.
7. Herbal products containing non-herbal ingredients other than vitamins and minerals are currently disallowed. However, the Directive may in the future be amended to allow such ingredients, although verifying their safety to the satisfaction of the HMPC is likely to be challenging and very expensive.
8. Increased cost to consumer and restriction of freedom of choice given that significant compliance costs will apply, which will be passed on to the end user, making the cost of products uneconomic for some and limiting their right to make their own health choice.
9. Committee control. Authorisations are controlled by the HMPC, which is weighted strongly towards drug pharmacologists/cognosists, as opposed to practicing medical herbalists and others with specific expertise on traditional medical practices.
10. Impact on non-European herbal suppliers. Many herbs potentially eligible under the THMPD scheme are produced by small-holder farmers and communities in non-EU countries. If products containing such herbs are disallowed as botanical-containing food supplements, and are also not able to be licenced under the THMPD scheme, these rural communities could be impacted very seriously.
As the European directive’s final implementation date April 2011 is approaching, UK’s Chinese medicine profession is witnessing a historical moment. The current crisis can be temporarily alleviated if one of these issues is solved: on the one hand, if practitioners are given statutory regulation status, they may continue to prescribe the currently unlicensed Chinese medicine to their patients, and on the other hand, if the new European directive is amended to no longer require Chinese medicine to obtain licenses, they will continue to be widely available to the public. Currently, neither possibility is close to realising, meaning that UK consumers face the prospect of losing complete access to many Chinese medicines that they are customised to use.
Originally posted by cybertroy
I assure you we are in a war. Might not be guns. But, we better nail these bastards to the wall, figuratively. Justice must come to Big Pharma.
Spread the truth, this is one way we will destroy them.
Originally posted by soficrow
reply to post by Spiro
First, they burned the witches who nurtured and cared for the villagers. Then, they took over our healthcare. Now, they're doing it again.
Originally posted by Zanti Misfit
reply to post by Boomer1941
This just in................Mike Savage Rocks ! .......LOL
Rise up and take the power back,
it's time that The fat cats had a heart attack,
you know that Their time is coming to an end,
we have to Unify and watch our flag ascend,
so come on
They will not force us
They will stop degrading us
They will not control us
We will be victorious,
so come on
Originally posted by rajaten
reply to post by Whiffer Nippets
What sort of vitamins are good?\
Do you take just a multivitamin?